Medpace Holdings, Inc. (NASDAQ:MEDP) Stock Position Lowered by Global Retirement Partners LLC

Global Retirement Partners LLC trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 19.4% during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 137 shares of the company’s stock after selling 33 shares during the period. Global Retirement Partners LLC’s holdings in Medpace were worth $46,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MEDP. Private Advisor Group LLC grew its holdings in shares of Medpace by 29.7% during the third quarter. Private Advisor Group LLC now owns 1,448 shares of the company’s stock valued at $483,000 after buying an additional 332 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Medpace by 17.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,243 shares of the company’s stock valued at $412,000 after purchasing an additional 185 shares during the period. Wealth Enhancement Advisory Services LLC lifted its position in shares of Medpace by 80.3% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 2,422 shares of the company’s stock worth $808,000 after purchasing an additional 1,079 shares in the last quarter. US Bancorp DE lifted its position in shares of Medpace by 59.3% in the third quarter. US Bancorp DE now owns 8,100 shares of the company’s stock worth $2,704,000 after purchasing an additional 3,016 shares in the last quarter. Finally, Stephens Inc. AR boosted its holdings in shares of Medpace by 16.4% during the third quarter. Stephens Inc. AR now owns 717 shares of the company’s stock worth $239,000 after purchasing an additional 101 shares during the period. 77.98% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Ratings Changes

Separately, Robert W. Baird increased their target price on shares of Medpace from $354.00 to $362.00 and gave the stock a “neutral” rating in a research report on Monday, January 27th. Seven analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $381.44.

Medpace Stock Up 0.4 %

NASDAQ MEDP opened at $327.32 on Friday. The stock has a market capitalization of $9.97 billion, a PE ratio of 25.92, a price-to-earnings-growth ratio of 3.81 and a beta of 1.36. Medpace Holdings, Inc. has a 12-month low of $302.01 and a 12-month high of $459.77. The company has a 50 day moving average price of $342.66 and a two-hundred day moving average price of $345.44.

Medpace (NASDAQ:MEDP) last released its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. As a group, equities analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current year.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.